News
The Details: Kinder Morgan reported quarterly earnings of 28 cents per share, which beat the analyst consensus estimate of 27 ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara ...
For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...
Johnson & Johnson on Wednesday reported second quarter results that topped estimates and the company lifted its full-year outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results